2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
21
Carcinoma, Transitional Cell
17
Anus Neoplasms
17
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
11
Appendiceal Neoplasms
11
Stomach Neoplasms
10
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Urologic Neoplasms
4
Sarcoma
4
Carcinoma
4
Anal Canal Carcinoma
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Recurrence
3
Pseudomyxoma Peritonei
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Sunitinib
3
Specimen Handling
3
Paclitaxel
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Biopsy
3
Abiraterone Acetate
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Suspensions
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts